HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $41 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Syndax Pharmaceuticals (NASDAQ:SNDX) and maintained a price target of $41.
July 29, 2024 | 5:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Syndax Pharmaceuticals and maintained a price target of $41.
The reiteration of a Buy rating and the maintenance of a $41 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100